{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:37:04Z","timestamp":1781797024863,"version":"3.54.5"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.clon.2021.09.015","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T22:09:06Z","timestamp":1633990146000},"page":"179-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Outcomes Following Hypofractionated Stereotactic Radiotherapy to the Cavity After Surgery for Melanoma Brain Metastases"],"prefix":"10.1016","volume":"34","author":[{"given":"J.","family":"Gallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Garimall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Huo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Foote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Pinkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clon.2021.09.015_bib1","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1038\/bjc.2011.178","article-title":"Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens","volume":"104","author":"Chiarion-Sileni","year":"2011","journal-title":"Br J Canc"},{"key":"10.1016\/j.clon.2021.09.015_bib2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12885-018-4374-x","article-title":"Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies","volume":"18","author":"Vosoughi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clon.2021.09.015_bib3","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ijrobp.2015.04.032","article-title":"Competing risk analysis of neurologic versus nonneurologic death in patients undergoing radiosurgical salvage after whole-brain radiation therapy failure: who actually dies of their brain metastases?","volume":"92","author":"Lucas","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2021.09.015_bib4","doi-asserted-by":"crossref","first-page":"E860","DOI":"10.1093\/neuros\/nyz162","article-title":"Image-guided, linac-based, surgical cavity-hypofractionated stereotactic radiotherapy in 5 daily fractions for brain metastases","volume":"85","author":"Soliman","year":"2019","journal-title":"Clin Neurosurg"},{"key":"10.1016\/j.clon.2021.09.015_bib5","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study","volume":"29","author":"Kocher","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib7","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib8","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jamaoncol.2020.4630","article-title":"Multi-institutional analysis of prognostic factors and outcomes after hypofractionated stereotactic radiotherapy to the resection cavity in patients with brain metastases","volume":"6","author":"Eitz","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11060-017-2394-z","article-title":"Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases","volume":"132","author":"Minniti","year":"2017","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11060-019-03383-w","article-title":"Evidence of dose-response following hypofractionated stereotactic radiotherapy to the cavity after surgery for brain metastases","volume":"146","author":"Garimall","year":"2020","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ijrobp.2018.10.038","article-title":"Single versus multifraction stereotactic radiosurgery for large brain metastases: an international meta-analysis of 24 trials","volume":"103","author":"Lehrer","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2021.09.015_bib12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.canrad.2016.06.010","article-title":"Stereotactic radiotherapy following surgery for brain metastasis: predictive factors for local control and radionecrosis","volume":"21","author":"Dor\u00e9","year":"2017","journal-title":"Canc Radiother"},{"key":"10.1016\/j.clon.2021.09.015_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijrobp.2020.10.034","article-title":"Tumor control probability of radiosurgery and fractionated stereotactic radiosurgery for brain metastases","volume":"110","author":"Redmond","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2021.09.015_bib14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ijrobp.2013.05.015","article-title":"Challenges with the diagnosis and treatment of cerebral radiation necrosis","volume":"87","author":"Chao","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2021.09.015_bib15","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2019.11.015","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment \u2013 Update 2019","volume":"126","author":"Garbe","year":"2020","journal-title":"Eur J Canc"},{"key":"10.1016\/j.clon.2021.09.015_bib16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib17","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib18","doi-asserted-by":"crossref","first-page":"TPS9600","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9600","article-title":"A\u00a0phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC-X Trial)","volume":"37","author":"Gonzalez","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib19","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1016\/S1470-2045(18)30508-4","article-title":"Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation \u2013 authors\u2019 reply","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib20","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S1470-2045(18)30439-X","article-title":"Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation","volume":"19","author":"Kruser","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib21","doi-asserted-by":"crossref","first-page":"E50","DOI":"10.1016\/S0360-3016(19)30524-3","article-title":"Incidence of radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy","volume":"103","author":"Glenn","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1001\/jamaoncol.2017.3993","article-title":"Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation","volume":"4","author":"Martin","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s11060-017-2442-8","article-title":"The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies","volume":"133","author":"Kim","year":"2017","journal-title":"J\u00a0Neuro Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib24","first-page":"17","article-title":"Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?","volume":"125","author":"Colaco","year":"2016","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.clon.2021.09.015_bib25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13014-020-1485-8","article-title":"Stereotactic radiosurgery combined with targeted immunotherapy in patients with melanoma brain metastasis","volume":"15","author":"Hadi","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib26","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ijrobp.2016.01.038","article-title":"Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: consensus guidelines from the Eastern Cooperative Oncology Group (ECOG)","volume":"95","author":"Anker","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2021.09.015_bib27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1259\/0007-1285-62-740-679","article-title":"The linear-quadratic formula and progress in fractionated radiotherapy","volume":"62","author":"Fowler","year":"1989","journal-title":"Br J Radiol"},{"key":"10.1016\/j.clon.2021.09.015_bib28","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/cncr.33459","article-title":"Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies","volume":"127","author":"Bander","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2021.09.015_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijrobp.2020.08.013","article-title":"Single- and multifraction stereotactic radiosurgery dose\/volume tolerances of the brain","volume":"110","author":"Milano","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2021.09.015_bib30","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ijrobp.2019.12.002","article-title":"Adverse radiation effect after hypofractionated stereotactic radiosurgery in 5 daily fractions for surgical cavities and intact brain metastases","volume":"106","author":"Faruqi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2021.09.015_bib31","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.adro.2017.07.003","article-title":"Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents","volume":"2","author":"Acharya","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.clon.2021.09.015_bib32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-019-0588-y","article-title":"Stereotactic radiosurgery combined with nivolumab or ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity","volume":"7","author":"Minniti","year":"2019","journal-title":"J\u00a0Immunother Canc"},{"key":"10.1016\/j.clon.2021.09.015_bib33","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1002\/cncr.30138","article-title":"Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery","volume":"122","author":"Qian","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clon.2021.09.015_bib34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ijrobp.2013.07.034","article-title":"Risk of leptomeningeal disease in patients treated with stereotactic radiosurgery targeting the postoperative resection cavity for brain metastases","volume":"87","author":"Atalar","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2021.09.015_bib35","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11060-014-1417-2","article-title":"Fractionated stereotactic radiotherapy to the post-operative cavity for radioresistant and radiosensitive brain metastases","volume":"118","author":"Ahmed","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.clon.2021.09.015_bib36","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11060-019-03233-9","article-title":"Fractionated stereotactic radiotherapy for local control of resected brain metastases","volume":"144","author":"Traylor","year":"2019","journal-title":"J Neurooncol"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655521003502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655521003502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:50:11Z","timestamp":1760543411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655521003502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0936655521003502"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2021.09.015","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes Following Hypofractionated Stereotactic Radiotherapy to the Cavity After Surgery for Melanoma Brain Metastases","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2021.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}